IL-7 Signalling Represses Bcl-6 and the TFH Gene Program
Overview
Authors
Affiliations
The transcriptional repressor Bcl-6 is linked to the development of both CD4(+) T follicular helper (TFH) and central memory T (TCM) cells. Here, we demonstrate that in response to decreased IL-2 signalling, T helper 1 (TH1) cells upregulate Bcl-6 and co-initiate TFH- and TCM-like gene programs, including expression of the cytokine receptors IL-6Rα and IL-7R. Exposure of this potentially bi-potent cell population to IL-6 favours the TFH gene program, whereas IL-7 signalling represses TFH-associated genes including Bcl6 and Cxcr5, but not the TCM-related genes Klf2 and Sell. Mechanistically, IL-7-dependent activation of STAT5 contributes to Bcl-6 repression. Importantly, antigen-specific IL-6Rα(+)IL-7R(+) CD4(+) T cells emerge from the effector population at late time points post influenza infection. These data support a novel role for IL-7 in the repression of the TFH gene program and evoke a divergent regulatory mechanism by which post-effector TH1 cells may contribute to long-term cell-mediated and humoral immunity.
Aiolos promotes CXCR3 expression on Th1 cells via positive regulation of IFN-γ/STAT1 signaling.
Leonard M, Jones D, Read K, Pokhrel S, Tuazon J, Warren R JCI Insight. 2024; 10(1.
PMID: 39560988 PMC: 11721307. DOI: 10.1172/jci.insight.180287.
Tsurui R, Yamada H, Natori T, Yoshimura M, Akasaki Y, Kawahara S J Transl Autoimmun. 2024; 9:100258.
PMID: 39554252 PMC: 11567946. DOI: 10.1016/j.jtauto.2024.100258.
IL-7 promotes mRNA vaccine-induced long-term immunity.
Wang L, Wan J, He W, Wang Z, Wu Q, Zhou M J Nanobiotechnology. 2024; 22(1):716.
PMID: 39550592 PMC: 11568559. DOI: 10.1186/s12951-024-02993-5.
ERBB2 is a potential diagnostic and prognostic biomarker in renal clear cell carcinoma.
Gao W, Chen L, Bao L, He N, Hu T, Lai C Sci Rep. 2024; 14(1):22775.
PMID: 39353993 PMC: 11445465. DOI: 10.1038/s41598-024-73574-7.
Transcriptional regulation of Tfh dynamics and the formation of immunological synapses.
Kim Y, Choi J, Choi Y Exp Mol Med. 2024; 56(6):1365-1372.
PMID: 38825646 PMC: 11263543. DOI: 10.1038/s12276-024-01254-7.